What the Research Says
Noopept was developed at the Russian Academy of Medical Sciences and has been studied primarily in Russian clinical literature. Ostrovskaya et al. (2007) demonstrated its neurotrophic properties, showing increased BDNF and NGF expression. Gudasheva et al. (1997) established its potency at 1000x piracetam by weight. Russian clinical trials have shown cognitive benefits in patients with mild cognitive impairment and post-stroke cognitive deficits. Western clinical trials are limited, and most evidence comes from preclinical models and Russian clinical literature.
